Target intelligence / Profile preview

Potassium voltage-gated channel subfamily S member 2 (KCNS2 (Kv9.2))

Target
KCNS2 (Kv9.2)
Molecular classification
Ion channel, Voltage-gated potassium channel complex, Delayed-rectifier potassium channel subunit
01

Overview

KCNS2 encodes Potassium voltage-gated channel subfamily S member 2 (Kv9.2), an “electrically silent” alpha subunit that does not form functional potassium channels on its own but instead coassembles with pore-forming subunits such as Kv2.1 and Kv2.2, modifying their activation and inactivation kinetics, voltage dependencies, and expression. This dynamic modulation fine-tunes neuronal excitability and signal transduction, especially in brain regions like the cortex, hippocampus, and cerebellum. Mutations or deletions in KCNS2 have been associated with essential tremor and neurodevelopmental disorders, and expression changes have been linked to neurodegenerative processes. The subunit functions in potassium ion transport but is not itself pore-forming, instead acting as a channel regulator. No direct pharmacological modulators are available or in clinical use for KCNS2, and its status as a disease biomarker or safety issue is theoretical at this stage.

Other names
Kv9.2KIAA1144Delayed-rectifier potassium channel regulatory subunit KCNS2Delayed-rectifier K(+) channel alpha subunit 2Delayed-rectifier potassium channel subunit Kv9.2Potassium voltage-gated channel modifier subfamily S member 2HCNS2KCNS2_HUMAN
02

Biological functions

Modulation of neuronal action potentialRegulation of potassium ion transmembrane transportFine-tuning neuronal excitability (through altered channel kinetics and voltage sensitivity)Cell proliferation (modulation role suggested in neuronal signaling)
03

Disease associations

Essential tremorNeurodevelopmental disordersPotential involvement in neurodegenerative diseaseOther disorders affecting central nervous system function
04

Safety considerations

As KCNS2 modulates neuronal excitability, theoretical concerns relate to off-target effects on CNS function (e.g., seizures, tremors) if specifically antagonized or agonized, but no direct clinical data is reported

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily S member 2 (KCNS2 (Kv9.2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily S member 2 (KCNS2 (Kv9.2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call